Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial

Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi; International Breast Cancer Study Group Trial 23-01 investigators

doi:10.1016/S1470-2045(13)70035-4

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial

Viviana Galimberti, Bernard F Cole, Stefano Zurrida, Giuseppe Viale, Alberto Luini, Paolo Veronesi, Paola Baratella, Camelia Chifu, Manuela Sargenti, Mattia Intra, Oreste Gentilini, Mauro G Mastropasqua, Giovanni Mazzarol, Samuele Massarut, Jean-Rémi Garbay, Janez Zgajnar, Hanne Galatius, Angelo Recalcati, David Littlejohn, Monika BamertMarco Colleoni, Karen N Price, Meredith M Regan, Aron Goldhirsch, Alan S Coates, Richard D Gelber, Umberto Veronesi, International Breast Cancer Study Group Trial 23-01 investigators

Brystkirurgi

1063 Citationer (Scopus)

Abstract

For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm.

Originalsprog	Engelsk
Tidsskrift	The Lancet Oncology
Vol/bind	14
Udgave nummer	4
Sider (fra-til)	297-305
Antal sider	9
ISSN	1470-2045
DOI	https://doi.org/10.1016/S1470-2045(13)70035-4
Status	Udgivet - apr. 2013

Adgang til dokumentet

10.1016/S1470-2045(13)70035-4

Citationsformater

Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., Gentilini, O., Mastropasqua, M. G., Mazzarol, G., Massarut, S., Garbay, J.-R., Zgajnar, J., Galatius, H., Recalcati, A., Littlejohn, D., ... International Breast Cancer Study Group Trial 23-01 investigators (2013). Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. The Lancet Oncology, 14(4), 297-305. https://doi.org/10.1016/S1470-2045(13)70035-4

Galimberti, V, Cole, BF, Zurrida, S, Viale, G, Luini, A, Veronesi, P, Baratella, P, Chifu, C, Sargenti, M, Intra, M, Gentilini, O, Mastropasqua, MG, Mazzarol, G, Massarut, S, Garbay, J-R, Zgajnar, J, Galatius, H, Recalcati, A, Littlejohn, D, Bamert, M, Colleoni, M, Price, KN, Regan, MM, Goldhirsch, A, Coates, AS, Gelber, RD, Veronesi, U & International Breast Cancer Study Group Trial 23-01 investigators 2013, 'Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial', The Lancet Oncology, bind 14, nr. 4, s. 297-305. https://doi.org/10.1016/S1470-2045(13)70035-4

@article{d295ae4bdf0341c7b8259d48f5752f86,

title = "Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial",

abstract = "For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm.",

keywords = "Adult, Aged, Axilla, Breast Neoplasms, Disease-Free Survival, Female, Follow-Up Studies, Humans, Lymph Nodes, Lymphatic Metastasis, Middle Aged, Neoplasm Grading, Neoplasm Micrometastasis, Sentinel Lymph Node Biopsy, Treatment Outcome",

author = "Viviana Galimberti and Cole, {Bernard F} and Stefano Zurrida and Giuseppe Viale and Alberto Luini and Paolo Veronesi and Paola Baratella and Camelia Chifu and Manuela Sargenti and Mattia Intra and Oreste Gentilini and Mastropasqua, {Mauro G} and Giovanni Mazzarol and Samuele Massarut and Jean-R{\'e}mi Garbay and Janez Zgajnar and Hanne Galatius and Angelo Recalcati and David Littlejohn and Monika Bamert and Marco Colleoni and Price, {Karen N} and Regan, {Meredith M} and Aron Goldhirsch and Coates, {Alan S} and Gelber, {Richard D} and Umberto Veronesi and {International Breast Cancer Study Group Trial 23-01 investigators}",

year = "2013",

month = apr,

doi = "10.1016/S1470-2045(13)70035-4",

language = "English",

volume = "14",

pages = "297--305",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01)

T2 - a phase 3 randomised controlled trial

AU - Galimberti, Viviana

AU - Cole, Bernard F

AU - Zurrida, Stefano

AU - Viale, Giuseppe

AU - Luini, Alberto

AU - Veronesi, Paolo

AU - Baratella, Paola

AU - Chifu, Camelia

AU - Sargenti, Manuela

AU - Intra, Mattia

AU - Gentilini, Oreste

AU - Mastropasqua, Mauro G

AU - Mazzarol, Giovanni

AU - Massarut, Samuele

AU - Garbay, Jean-Rémi

AU - Zgajnar, Janez

AU - Galatius, Hanne

AU - Recalcati, Angelo

AU - Littlejohn, David

AU - Bamert, Monika

AU - Colleoni, Marco

AU - Price, Karen N

AU - Regan, Meredith M

AU - Goldhirsch, Aron

AU - Coates, Alan S

AU - Gelber, Richard D

AU - Veronesi, Umberto

AU - International Breast Cancer Study Group Trial 23-01 investigators

PY - 2013/4

Y1 - 2013/4

N2 - For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm.

AB - For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm.

KW - Adult

KW - Aged

KW - Axilla

KW - Breast Neoplasms

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Lymph Nodes

KW - Lymphatic Metastasis

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Micrometastasis

KW - Sentinel Lymph Node Biopsy

KW - Treatment Outcome

U2 - 10.1016/S1470-2045(13)70035-4

DO - 10.1016/S1470-2045(13)70035-4

M3 - Journal article

C2 - 23491275

SN - 1470-2045

VL - 14

SP - 297

EP - 305

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 4

ER -

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater